Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cetuximab (erbitux).

Literature DB >> 20167650

Cetuximab (erbitux).

Abstract

Cetuximab, a recombinant chimeric monoclonal antibody, has been successfully used in the treatment of the head and neck and colorectal cancers. We present a review of its mechanism of action, indications, side effects and economic issues, accompanied by a clinical example from our institution.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2010 PMID： 20167650 PMCID： PMC7964212 DOI： 10.3174/ajnr.A2054

Source DB: PubMed Journal: AJNR Am J Neuroradiol ISSN： 0195-6108 Impact factor: 3.825

12 in total

1. Cetuximab in colon cancer.

Authors: Alan F Holmer
Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245

Review 2. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.

Authors: Siu-Fun Wong
Journal: Clin Ther Date: 2005-06 Impact factor: 3.393

3. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.

Authors: Tito Fojo; Christine Grady
Journal: J Natl Cancer Inst Date: 2009-06-29 Impact factor: 13.506

4. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

Authors: Nicole Mittmann; Heather-Jane Au; Dongsheng Tu; Christopher J O'Callaghan; Pierre K Isogai; Christos S Karapetis; John R Zalcberg; William K Evans; Malcolm J Moore; Jehan Siddiqui; Brian Findlay; Bruce Colwell; John Simes; Peter Gibbs; Matthew Links; Niall C Tebbutt; Derek J Jonker
Journal: J Natl Cancer Inst Date: 2009-08-07 Impact factor: 13.506

5. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.

Authors: Philipp Steiner; Christopher Joynes; Rajiv Bassi; Su Wang; James R Tonra; Yaron R Hadari; Daniel J Hicklin
Journal: Clin Cancer Res Date: 2007-03-01 Impact factor: 12.531

Review 6. Review of epidermal growth factor receptor biology.

Authors: Roy S Herbst
Journal: Int J Radiat Oncol Biol Phys Date: 2004 Impact factor: 7.038

7. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.

Authors: Ariel Birnbaum; Thomas Dipetrillo; Ritesh Rathore; Elliott Anderson; Harry Wanebo; Yacoub Puthwala; Donald Joyce; Howard Safran; Denise Henderson; Theresa Kennedy; Neal Ready; Terence Tai-Weng Sio
Journal: Am J Clin Oncol Date: 2010-04 Impact factor: 2.339

Review 8. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.

Authors: Stephanie K A Blick; Lesley J Scott
Journal: Drugs Date: 2007 Impact factor: 9.546

Review 9. HER1/EGFR targeting: refining the strategy.

Authors: Román Pérez-Soler
Journal: Oncologist Date: 2004

10. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.

Authors: Michael I Koukourakis; Pelagia G Tsoutsou; Antonios Karpouzis; Maria Tsiarkatsi; Ilias Karapantzos; Vassilios Daniilidis; Constantinos Kouskoukis
Journal: Int J Radiat Oncol Biol Phys Date: 2009-09-08 Impact factor: 7.038

17 in total

1. Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.

Authors: E Merit Reyes-Reyes; Francesca R Šalipur; Mitra Shams; Matthew K Forsthoefel; Paula J Bates
Journal: Mol Oncol Date: 2015-04-09 Impact factor: 6.603

2. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.

Authors: Hsin-Wei Liao; Jung-Mao Hsu; Weiya Xia; Hung-Ling Wang; Ying-Nai Wang; Wei-Chao Chang; Stefan T Arold; Chao-Kai Chou; Pei-Hsiang Tsou; Hirohito Yamaguchi; Yueh-Fu Fang; Hong-Jen Lee; Heng-Huan Lee; Shyh-Kuan Tai; Mhu-Hwa Yang; Maria P Morelli; Malabika Sen; John E Ladbury; Chung-Hsuan Chen; Jennifer R Grandis; Scott Kopetz; Mien-Chie Hung
Journal: J Clin Invest Date: 2015-11-16 Impact factor: 14.808

3. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.

Authors: Lei Zhao; Qiao-Qiao Li; Rui Zhang; Mian Xi; Yi-Ji Liao; Dong Qian; Li-Ru He; Yi-Xin Zeng; Dan Xie; Meng-Zhong Liu
Journal: Tumour Biol Date: 2012-03-03

Review 4. Molecularly targeted drugs for metastatic colorectal cancer.

Authors: Ying-dong Cheng; Hua Yang; Guo-qing Chen; Zhi-cao Zhang
Journal: Drug Des Devel Ther Date: 2013-11-01 Impact factor: 4.162

5. Effective binding of a phosphatidylserine-targeting antibody to Ebola virus infected cells and purified virions.

Authors: S D Dowall; V A Graham; K Corbin-Lickfett; C Empig; K Schlunegger; C B Bruce; L Easterbrook; R Hewson
Journal: J Immunol Res Date: 2015-03-01 Impact factor: 4.818

Review 6. Emerging functions of the EGFR in cancer.

Authors: Sara Sigismund; Daniele Avanzato; Letizia Lanzetti
Journal: Mol Oncol Date: 2017-11-27 Impact factor: 6.603

Review 7. Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment.

Authors: Voon Yee-Lin; Wong Pooi-Fong; Alan Khoo Soo-Beng
Journal: Mini Rev Med Chem Date: 2018 Impact factor: 3.862

8. Single-Molecule 3D Images of "Hole-Hole" IgG1 Homodimers by Individual-Particle Electron Tomography.

Authors: Dongsheng Lei; Jianfang Liu; Hongbin Liu; Thomas E Cleveland; John P Marino; Ming Lei; Gang Ren
Journal: Sci Rep Date: 2019-06-20 Impact factor: 4.379

9. Cetuximab Conjugated with Octreotide and Entrapped Calcium Alginate-beads for Targeting Somatostatin Receptors.

Authors: Ahmed A H Abdellatif; Mohamed A Ibrahim; Mohammed A Amin; Hamzah Maswadeh; Muhammed N Alwehaibi; Sultan N Al-Harbi; Zayed A Alharbi; Hamdoon A Mohammed; Ahmed B M Mehany; Imran Saleem
Journal: Sci Rep Date: 2020-03-13 Impact factor: 4.379

10. EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.

Authors: Györgyi A Nelhűbel; Mihály Cserepes; Balázs Szabó; Dóra Türk; Adél Kárpáti; István Kenessey; Erzsébet Rásó; Tamás Barbai; Zita Hegedűs; Viktória László; Bálint Szokol; Judit Dobos; László Őrfi; József Tóvári
Journal: Pathol Oncol Res Date: 2021-05-03 Impact factor: 3.201